共 50 条
- [32] Impact of Patisiran, an RNAi Therapeutic, on Diarrhea Symptoms in Patients With Hereditary Transthyretin-Mediated Amyloidosis AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1657 - S1657
- [38] Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis ANNALS OF MEDICINE AND SURGERY, 2025, 87 (01): : 20 - 23
- [39] Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (03): : 153 - 162